The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Piriprost     5-[(7R,8S)-7-hydroxy-8- [(E,3S)-3...

Synonyms: Piriprostium, SureCN571149, CHEMBL2105239, AC1O5NJY, LS-177493, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Piriprost

 

High impact information on Piriprost

 

Biological context of Piriprost

  • This performed in presence of increasing concentration of the 5-lipoxygenase inhibitors AA-861 or U-60,257 caused a dose-dependent inhibition of the release of all LTs with an IC50 of approximately 10(-8) to 10(-7) M and 10(-6) M, respectively [8].
  • U-60,257 had virtually no effect on oxygen radical production and degranulation, but chemotaxis was moderately suppressed [9].
  • We therefore studied the effects of piriprost (U 60257), a putative leukotriene synthesis inhibitor, on thirteen fetal lambs at 137 to 140 days gestation [10].
  • Inhibition of the presumably leukotriene-dependent component of antigen-induced bronchoconstriction in the guinea pig by piriprost (U-60,257) [11].
  • Since leukotriene release might be associated with leukocyte activation in this model, seven additional dogs were pretreated by inhalation of 10 mg of the leukotriene inhibitor U-60,257 [12].
 

Anatomical context of Piriprost

 

Associations of Piriprost with other chemical compounds

 

Gene context of Piriprost

  • Piriprost, a specific inhibitor of 5-lipoxygenase, inhibits proliferation of these cell lines up to 95% with 50% cell inhibition at approximately 3 x 10(-5) M [20].
  • The results are consistent with the conclusion that piriprost acts as an inhibitor of the 5-lipoxygenase reaction and that its activity in intact cells is not likely to involve the inhibition of the LTC synthase [15].
  • U-60,257 did not inhibit the cyclooxygenase of human polymorphonuclear leukocytes [21].
  • On the other hand, U-60,257 inhibited glutathione S-transferase activity of rat basophil leukemia cells (ID50, 37 microM), suggesting that this compound may inhibit the last step in LTC biosynthesis [21].
  • Piriprost behaves thus as a specific and apparently competitive antagonist of fMLP: this action does not seem to involve lipoxygenase inhibition and might be exerted at the level of the fMLP receptor or its associated mechanisms of transduction [22].
 

Analytical, diagnostic and therapeutic context of Piriprost

References

  1. Role of lipids in bone marrow-induced pulmonary edema. Selig, W.M., Burhop, K.E., Malik, A.B. J. Appl. Physiol. (1987) [Pubmed]
  2. U-60,257 inhibits O3-induced bronchial hyperreactivity in the guinea pig. Murlas, C., Lee, H.K. Prostaglandins (1985) [Pubmed]
  3. Effects of the 5-lipoxygenase inhibitors AA-863 and U-60,257 on human glioma cell lines. Gáti, I., Bergström, M., Csóka, K., Muhr, C., Carlsson, J. Prostaglandins Leukot. Essent. Fatty Acids (1990) [Pubmed]
  4. The activity of a new, novel inhibitor of leukotriene synthesis in rhesus monkey Ascaris reactors. Johnson, H.G., McNee, M.L., Bach, M.K., Smith, H.W. Int. Arch. Allergy Appl. Immunol. (1983) [Pubmed]
  5. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Tew, K.D., Bomber, A.M., Hoffman, S.J. Cancer Res. (1988) [Pubmed]
  6. The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. Abeysinghe, R.D., Roberts, P.J., Cooper, C.E., MacLean, K.H., Hider, R.C., Porter, J.B. J. Biol. Chem. (1996) [Pubmed]
  7. Lipoxygenase metabolism is required for interleukin-3 dependent proliferation and cell cycle progression of the human M-07e cell line. Miller, A.M., Allen, B.S., Ziboh, V. J. Cell. Physiol. (1997) [Pubmed]
  8. Release of leukotrienes into the perfusate of calcium-ionophore stimulated rabbit lungs. Influence of 5-lipoxygenase inhibitors. Schulz, R., Seeger, W. Biochem. Pharmacol. (1986) [Pubmed]
  9. A comparative study on the effects of inhibitors of the lipoxygenase pathway on neutrophil function. Inhibitory effects on neutrophil function may not be attributed to inhibition of the lipoxygenase pathway. Ozaki, Y., Ohashi, T., Niwa, Y. Biochem. Pharmacol. (1986) [Pubmed]
  10. Piriprost: a putative leukotriene synthesis inhibitor increases pulmonary blood flow in fetal lambs. Lebidois, J., Soifer, S.J., Clyman, R.I., Heymann, M.A. Pediatr. Res. (1987) [Pubmed]
  11. Inhibition of the presumably leukotriene-dependent component of antigen-induced bronchoconstriction in the guinea pig by piriprost (U-60,257). Bach, M.K., Griffin, R.L., Richards, I.M. Int. Arch. Allergy Appl. Immunol. (1985) [Pubmed]
  12. Haemodynamic, gasometric and haematological effects of air infusion in dogs: leukotriene inhibition with U-60,257. Domb, M., Goldstein, J., Vincent, J.L., Azimi, G., Lignian, H., Bernard, A., Brimioulle, S., Lejeune, P., Duchateau, J. Bulletin européen de physiopathologie respiratoire. (1986) [Pubmed]
  13. Variable effects of human and canine polymorphonuclear leucocytes on vascular smooth muscle tone. Gonzales, J., Mehta, J.L., Lawson, D.L., Nichols, W.W., Nicolini, F.A. Cardiovasc. Res. (1992) [Pubmed]
  14. Pharmacological modulation of responses of guinea-pig airways contracted with antigen and calcium ionophore A23187. Burka, J.F. Br. J. Pharmacol. (1985) [Pubmed]
  15. Experiments on the mode of action of piriprost (U-60,257), an inhibitor of leukotriene formation in cloned mouse mast cells and in rat basophil leukemia cells. Bach, M.K., Brashler, J.R., White, G.J., Galli, S.J. Biochem. Pharmacol. (1987) [Pubmed]
  16. Effect of 6,9-deepoxy-6,9-(phenylimino)-delta 6,8-prostaglandin 1(1) (U-60,257), an inhibitor of leukotriene synthesis, on human neutrophil function. Smith, R.J., Sun, F.F., Bowman, B.J., Iden, S.S., Smith, H.W., McGuire, J.C. Biochem. Biophys. Res. Commun. (1982) [Pubmed]
  17. Effect of inhaled piriprost (U-60, 257) a novel leukotriene inhibitor, on allergen and exercise induced bronchoconstriction in asthma. Mann, J.S., Robinson, C., Sheridan, A.Q., Clement, P., Bach, M.K., Holgate, S.T. Thorax (1986) [Pubmed]
  18. Effects of piriprost (U-60, 257B) and leukotrienes on alkaline phosphatase activity of rat endometrial stromal cells in vitro. Cejic, S.S., Kennedy, T.G. Prostaglandins (1991) [Pubmed]
  19. U-60,257 has no effect on the metabolism of arachidonic acid in nonstimulated human polymorphonuclear leukocytes. Dahl, M.L., Puustinen, T., Uotila, P. Res. Commun. Chem. Pathol. Pharmacol. (1984) [Pubmed]
  20. Antiproliferative effects of lipoxygenase inhibitors on malignant human hematopoietic cell lines. Snyder, D.S., Castro, R., Desforges, J.F. Exp. Hematol. (1989) [Pubmed]
  21. 6,9-deepoxy-6,9,-(phenylimino)-delta 6,8-prostaglandin I1, (U-60,257), a new inhibitor of leukotriene C and D synthesis: in vitro studies. Bach, M.K., Brashler, J.R., Smith, H.W., Fitzpatrick, F.A., Sun, F.F., McGuire, J.C. Prostaglandins (1982) [Pubmed]
  22. Effect of the 5-lipoxygenase inhibitor piriprost on superoxide production by human neutrophils. Flament, J., Schandene, L., Boeynaems, J.M. Prostaglandins Leukot. Essent. Fatty Acids (1988) [Pubmed]
  23. Stability studies on piriprost and piriprost potassium using high-performance liquid chromatography. Snider, B.G., Theis, D.L., Plaisted, S.M. J. Chromatogr. (1986) [Pubmed]
  24. Leukotrienes and histamine mediate IgE-dependent contractions of human bronchi: pharmacological evidence obtained with tissues from asthmatic and non-asthmatic subjects. Björck, T., Dahlén, S.E. Pulmonary pharmacology. (1993) [Pubmed]
  25. Pulmonary response to free fatty acid intravenous infusion in the rabbit: role of leukotrienes and the effect of prostacyclin. Arenas, G., Del Buono, R., Oyarzún, M.J., Donoso, P., Quijada, D. Arch. Biol. Med. Exp. (1989) [Pubmed]
  26. Inhibition of human platelet and neutrophil function by piriprost (U-60,257). Mehta, J.L., Mehta, P., Ward, M.B., Lawson, D. Prostaglandins, leukotrienes, and medicine. (1987) [Pubmed]
  27. Mass spectrometric analysis of 5-hydroxyeicosatetraenoic acid (5-HETE) in the perfusate of the isolated rat lung. Strife, R.J., Voelkel, N.F., Murphy, R.C. Am. Rev. Respir. Dis. (1987) [Pubmed]
 
WikiGenes - Universities